Study of 125,000 finds limited cancer-prevention benefit from aspirin

Date:

Share this article:

Del denne artikel:

New research indicates that the effect of aspirin against colorectal cancer may be limited and associated with risks.

A major review published in the Cochrane Library, cited by HealthDay, shows that daily aspirin use may increase the risk of serious bleeding.

There are also indications of a possible increased risk of bleeding in the brain.

The risk applies even at low doses. According to the researchers, the risk of bleeding begins from the moment a person starts taking the medication.

Any potential protective effect against cancer, by contrast, would only become apparent after more than ten years, if it occurs at all.

Also read: Women face greater risk of dying after heart attack, study finds

What does the study show?

The analysis is based on 10 randomized trials involving nearly 125,000 participants.

The researchers examined whether aspirin could prevent colon and rectal cancer or precancerous conditions in individuals at average risk.

During the first five to fifteen years, there was little or no protective effect.

Some studies suggested a possible benefit after long-term use, but the researchers assess the certainty of this evidence as very low.

Also read: Early findings offer new hope in fight against pancreatic cancer

Caution recommended

Aspirin and similar painkillers have been studied for several years as a possible means of cancer prevention.

Interest has partly focused on their effect on inflammatory processes in the body.

The researchers behind the review, who are affiliated with West China Hospital at Sichuan University, recommend consulting a doctor before starting aspirin to prevent cancer.

Overall, the review shows that the benefits for individuals at average risk are uncertain, while the side effects are well known and can be serious.

Also read: More hours of sleep may lead to weight loss, study shows

Sources: HealthDay, and Cochrane Library.

Also read: Can plant-based diets provide enough protein? Experts have the answer

This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.

Other articles

GLP-1 drugs like Ozempic may now be an option for a group of patients long left out

The 2026 American Diabetes Association guidance opens GLP-1 therapy to a new patient group.

Your gut bacteria may spread to the people around you more easily than anyone realized

A new Nature study finds gut microbes spread between people, sometimes across continents, faster than expected.

Low vitamin C may be quietly speeding up how fast your brain ages

A study of 2,044 older adults links lower plasma vitamin C to shrinking brain volume and weaker memory-network wiring.

Why rheumatoid arthritis attacks some joints and not others: The answer starts before birth

Oxford scientists say certain finger joints may be biologically primed for the disease before you are born.

GLP-1 drugs like Ozempic may now be an option for a group of patients long left out

The 2026 American Diabetes Association guidance opens GLP-1 therapy to a new patient group.

Your gut bacteria may spread to the people around you more easily than anyone realized

A new Nature study finds gut microbes spread between people, sometimes across continents, faster than expected.

Low vitamin C may be quietly speeding up how fast your brain ages

A study of 2,044 older adults links lower plasma vitamin C to shrinking brain volume and weaker memory-network wiring.